Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level823 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (419)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07515924 | Oral Gallium Maltolate for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 8 | Medical College of WisconsinOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05555550 | Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06613841 | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma(GBM) | recruiting | Early Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06959979 | Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma | recruiting | Early Phase 1 | 60 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Aug 26, 2026 | clinicaltrials |
| NCT07076472 | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma | recruiting | Early Phase 1 | 8 | Mayo ClinicOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07485049 | BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | recruiting | Early Phase 1 | 78 | Nader SanaiOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | active not recruiting | Early Phase 1 | 39 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05406700 | Niraparib In Recurrent IDH 1/2 Gliomas | active not recruiting | Early Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma(PRECISE) | not yet recruiting | Early Phase 1 | 12 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06942039 | Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation | recruiting | Early Phase 1 | 15 | C17 CouncilOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | recruiting | Early Phase 1 | 38 | Eben RosenthalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | recruiting | Early Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07655869 | [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma | recruiting | Early Phase 1 | 24 | Beijing Tiantan HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07648823 | Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma | recruiting | Early Phase 1 | 5 | Beijing Tiantan HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05651178 | Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients | active not recruiting | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06831526 | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | recruiting | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma(SENIPERA) | recruiting | Early Phase 1 | 36 | Aarhus University HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06636162 | Window of Opportunity Study of DSP-0390 in Gliomas | recruiting | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07017816 | A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.(JACOB) | recruiting | Early Phase 1 | 18 | Children's National Research InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | Huashan HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | active not recruiting | Early Phase 1 | 46 | Yale UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | active not recruiting | Early Phase 1 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | active not recruiting | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05182905 | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients | active not recruiting | Early Phase 1 | 97 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02933736 | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | active not recruiting | Early Phase 1 | 48 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | recruiting | Early Phase 1 | 12 | Stony Brook UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | active not recruiting | Early Phase 1 | 14 | Emory UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05553041 | 18F-Fluciclovine PET-MRI in High-grade Glioma | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07244666 | Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06072586 | A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions | recruiting | Early Phase 1 | 82 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05045027 | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | active not recruiting | Early Phase 1 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05717153 | Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma | recruiting | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07172178 | γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma | not yet recruiting | Early Phase 1 | 12 | Nanjing Medical UniversityOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT06552260 | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | recruiting | Early Phase 1 | 27 | Ugonma ChukwuekeOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | recruiting | Early Phase 1 | 12 | Oliver JonasOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT06424301 | Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma | recruiting | Early Phase 1 | 2 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05380349 | Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma | recruiting | Early Phase 1 | 10 | Swedish Medical CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06972602 | High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed | recruiting | Early Phase 1 | 10 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05432518 | Pilot Trial for Treatment of Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | AHS Cancer Control AlbertaOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | recruiting | Early Phase 1 | 15 | Zhongnan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials